LifeMD, Inc. announced the closing of a senior secured revolving credit facility with Citizens Bank, N.A., providing up to $50 million in total availability. The facility comprises $30 million of committed availability and an accordion feature allowing an additional $20 million, with a maturity date of January 2, 2029. At closing, no borrowings were outstanding, as LifeMD’s management expects existing cash balances and operating cash flow to fund its organic growth initiatives. Interest rates under the facility float at Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus 50 to 125 basis points; fees on unused committed amounts range from 0.225% to 0.30%, and no upfront fees were charged. CFO Marc Benathen highlighted the competitive pricing and financial flexibility the facility provides for corporate development and shareholder value–creating opportunities.

In collaboration with Novo Nordisk, LifeMD began offering the newly FDA-approved oral GLP-1 therapy Wegovy® (semaglutide) through its end-to-end telehealth platform. Eligible patients can access 1.5 mg and 4 mg doses for $149 per month; beginning April 15, 2026, the 4 mg dose will be priced at $199 per month while 9 mg and 25 mg pills will be offered at $299 per month. The FDA approval, supported by a 64-week Phase 3 trial demonstrating mean weight loss of 16.6% versus 2.7% for placebo, marks the first oral GLP-1 indicated for long-term weight maintenance and cardiovascular risk reduction. LifeMD’s integration with NovoCare® Pharmacy ensures virtual visits, nationwide diagnostic testing, coordinated pharmacy fulfillment, real-time tracking and streamlined billing for patients across all 50 states. CEO Justin Schreiber emphasized that the oral formulation broadens access for patients hesitant about injectable therapies and positions LifeMD as a preferred destination for evidence-based obesity care.